• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

My Decision to Receive CAR-T Cell Therapy for Multiple Myeloma

by | Jul 20, 2024 | Uncategorized

Source: CureToday articles I decided to receive CAR-T cell therapy for multiple myeloma when my previous regimen stopped working and now, I’m living my best life. Read More

Finding Support After a Myeloma Diagnosis

by | Jul 12, 2024 | Uncategorized

Source: CureToday articles I was diagnosed with myeloma more than two decades ago and am lucky to have support throughout. Read More

My Lifestyle as Someone With Multiple Myeloma

by | Jul 11, 2024 | Uncategorized

Source: CureToday articles Side effects from multiple myeloma, such as six inches of collapsed vertebrae, have made me adjust my lifestyle, but I make the most of what I can. Read More

How Bispecific Antibodies Work to Treat Multiple Myeloma

by | Jul 8, 2024 | Uncategorized

Source: CureToday articles One expert explains how bispecific antibodies are a ‘targeted and effective’ option for patients with multiple myeloma. Read More

Mapping the Proteogenomic Landscape of Multiple Myeloma: Implications for Targeted Therapy

by | Jul 8, 2024 | Uncategorized

Source: Pharmacy Times articles Researchers identify significant proteins involved in the growth and survival of malignant multiple myeloma cells. Read More

VIDEO: ‘More movement’ in nontransplant-eligible multiple myeloma population

by | Jul 6, 2024 | Uncategorized

CHICAGO — In this video, Sandra Mazzoni, DO, highlights data in nontransplant-eligible patients with multiple myeloma presented at ASCO Annual Meeting.“There are a lot of studies in the nontransplant-eligible population presented, and I think that that space has not...
« Older Entries
Next Entries »

Recent Content

  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
  • Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
  • A Year of Resilience: Looking Back After a Myeloma Diagnosis
  • Real-World Outcomes Show Efficacy, Safety of Ciltacabtagene Autoleucel in Relapsed, Refractory Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT